Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Developments examine located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By in... https://audreyg037jvg4.wikilinksnews.com/user